Genzyme Biosurgery Corporation

Development of novel biotherapeutic and biomaterial products aimed to improve the health of patients in the orthopaedics and post-surgical adhesive disease areas

Genzyme Biosurgery Corp. is part of globally-acting Genzyme Corporation. On 8 February 2005, Genzyme announced that it has acquired Verigen AG for $ 10 million in initial payments and potential additional payments of up to $ 40 million of the next six years - based upon the achievement of development and commercial milestones.

Henri A. Termeer, President, Chairman and CEO
Richard A. Moscicki, M.D., Senior VP, CMO
Michael S. Wyzga
Executive VP, Finance; Chief Financial and Accounting Officer

Henri A. Termeer, Chairman
Douglas A. Berthiaume
Gail K. Boudreaux
Robert J. Carpenter
Charles L. Cooney, Ph.D.
Victor J. Dzau, M.D.
Senator Connie Mack III
Richard F. Syron

55 Cambridge Parkway
Cambridge, MA 02142
USA

Genzyme Biosurgery develops a Fleming-Poff scale for use in assessing the efficacy of dermal fillers. The Fleming-Poff scale provides an objective reference scale for assessing the severity of nasal-labial folds by using a standardized facial image that has been changed to represent these wrinkles at various depths, on a six-point scale. Previous scales relied on different facial images to represent each wrinkle depth, which led to less objective measurements.

Genzyme Biosurgery markets a set of HA-based products, including Synvisc® (hylan G-F 20), for pain due to osteoarthritis of the knee, and the Sepra™, for improving the outcome of surgery by reducing the incidence of adhesions.
A product in the cell therapy business area called Epicel® (cultured epidermal autografts) is an autologous cell therapy designed for permanent skin replacement. Carticel® (autologous cultured chondrocytes) uses similar technology to renew a patient’s own cartilage cells to replace damaged cartilage in the knee.

Currently, several clinical studies are being undertaken including two phase 3 clinical studies on Synvisc® (osteoarthritis), a preclinical study on the use of Carticel®II in knee cartilage damage, a phase 3 study on adhesion prevention using Seprafilm™ II and a preclinical study using Sepragel® Ortho.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.